Navigation Links
ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth,Opportunities Conference

NEW YORK--(BUSINESS WIRE)--Jul 6, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Thursday, July 12, 2007 at 2:30 p.m. ET at the Mandarin Oriental Hotel, New York. Dr. Lewis will provide an overview of the Company and an update on its clinical development programs.

The presentation will be webcast live and can be accessed by visiting the Investor Relations section at www.ziopharm.com. The webcast will be archived for ninety days.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's a bility to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.

ZIOP-G

Contact

Investors
ZIOPHARM Investor Relations
Suzanne McKenna, 646-214-0703
smckenna@ziopharm.com
or
Media
Rx Communications
Tina Posterli, 917-322-2565
tposterli@rxir.com


'"/>




Related medicine technology :

1. ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR
2. ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR
3. ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR
4. ZIOPHARM Presents ZIO-201 Lymphoma Data at ISH
5. The Past, Present and Future of HLA Typing
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 Glycotope GmbH, ... today announces the appointment of Dr. Alfredo Zurlo ... is an oncologist with many years clinical experience and ... industries. His last role was at Mologen AG where ... Executive Board. Previously Dr. Zurlo held various positions at ...
(Date:4/28/2016)... FLINT, Mich. , April 28, 2016 /PRNewswire/ ... transaction . Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... it has signed a definitive agreement to acquire ... Advanced Specialty Pharmacy ("TNH"), a leading specialty pharmacy ... Van Nuys, California . In 2015, ...
(Date:4/28/2016)... 28, 2016 Research and Markets ... Surgery Products Market 2016-2020" report to their offering. ... The global plastic surgery products market is ... the period 2016-2020. , ,The growing adoption of laser ... growth of the market. Lasers are used to treat ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... , ... The number of chronically and seriously ill individuals is growing. Americans ... urgent need for highly skilled care managers and care coordinators. Care Excellence ... and retain care managers, and enhance their skills. , Care Excellence helps ...
(Date:4/28/2016)... ... , ... Sublime Beauty® is offering a special deal on its webstore. , Buy 1 product ... applied to the product with lesser value. In addition, a free bonus of 3 ... in products. , "So many women (men, too) love our products and get good results. ...
(Date:4/28/2016)... ... 28, 2016 , ... La Sirena Foods provides premium canned seafood, specifically, Tuna, ... looking to grow their market share in the USA. , "We are happy to ... Sirena Foods and indirectly with Otis McAllister , a leading global food ...
(Date:4/28/2016)... ... April 28, 2016 , ... The ... a new CDISC standard, Clinical Trial Registry (CTR) XML. Clinical trial registries ... will make it possible to build applications that generate submissions for multiple, ...
(Date:4/28/2016)... ... April 28, 2016 , ... Greener Hydroponics is now offering ... are frequently used by professional organic farmers and nurseries according to Sales Manager Joe ... of fabric pots. Our goal is to offer wholesale level pricing and ultra-fast shipping ...
Breaking Medicine News(10 mins):